Pacific Edge (PEB.NZ) Stock Price
Pacific Edge Price
Revenue has compounded at 19.7% per year over the past 19 years to 21.85 M NZD. Pacific Edge's net margin stands at -137.0%, up from -184.7% several years earlier. Analysts set a median price target of 0.13 NZD, implying 44.6% below the current price. Of 8 analysts, 0 rate the stock a buy — an overall Sell consensus.
Pacific Edge stock price
Pacific Edge business model & stock analysis
Frequently asked questions about Pacific Edge
The business model of Pacific Edge Ltd is centered around personalized medicine and diagnostic tests. The company specializes in developing and commercializing innovative molecular diagnostic tests that help in the detection and management of cancer. By leveraging advanced technologies, Pacific Edge aims to provide accurate, non-invasive, and cost-effective solutions for early detection and monitoring of various types of cancer. The company's focus on precision medicine enables healthcare professionals to make informed decisions regarding patient treatment, ultimately improving outcomes and reducing healthcare costs. Pacific Edge Ltd is committed to ongoing research and development to expand their portfolio of diagnostic tests and make a positive impact on global cancer care.
Pacific Edge Ltd is primarily active in the healthcare industry.
Some of the main competitors of Pacific Edge Ltd in the market include companies such as Exact Sciences Corp, Genomic Health Inc, and Myriad Genetics Inc.
Pacific Edge Ltd is a New Zealand-based biotechnology company. Established in 2001, Pacific Edge specializes in the discovery and development of diagnostic and prognostic tools for the early detection and monitoring of various cancers. With a focus on urology and the detection of bladder cancer, Pacific Edge has developed a range of proprietary diagnostic tests, including Cxbladder, which has gained recognition worldwide. The company has garnered partnerships and collaborations with various healthcare organizations and research institutes, enabling them to expand their portfolio and global presence. Pacific Edge Ltd continues to innovate and provide cutting-edge solutions in the field of cancer diagnostics.
Pacific Edge Ltd has achieved several significant milestones in its journey. The company successfully developed and commercialized its Cxbladder range of non-invasive, accurate bladder cancer diagnostics. It has established partnerships and distribution agreements with reputed healthcare organizations worldwide, expanding its market reach. Pacific Edge Ltd has also made advancements in its product portfolio, introducing innovative features and improvements to enhance diagnostic accuracy and patient outcomes. Additionally, the company has gained recognition from the medical community, receiving numerous awards and accolades for its groundbreaking diagnostic solutions. Overall, Pacific Edge Ltd has demonstrated relentless commitment to pioneering advancements in bladder cancer diagnostics, solidifying its position as a leader in the field.
Pacific Edge Ltd is primarily present in New Zealand, the United States, Australia, and Canada.
Pacific Edge Ltd represents a commitment to excellence, innovation, and cutting-edge technology within the healthcare industry. With a focus on precision medicine, the company strives to provide accurate and reliable diagnostic solutions for the early detection and monitoring of various cancers. Pacific Edge firmly believes in patient-centric care, ensuring that individuals receive timely and personalized treatment options. The company's corporate philosophy revolves around improving patient outcomes, enhancing healthcare practices, and driving sustainable growth through ongoing research and development. With Pacific Edge Ltd, investors can have confidence in a company that is dedicated to making a positive impact on cancer management worldwide.
Analysts currently set an average price target of 0.13 NZD for the Pacific Edge stock (median: 0.13 NZD), implying -44.6 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Pacific Edge stock: 0 recommend buying, 3 holding and 5 selling.
Converted at the current exchange rate, the Pacific Edge share trades at 0.11 EUR (0.23 NZD).
The Pacific Edge share (PEB.NZ) is listed on 4 stock exchanges, including: ASX (PEB.AX).
Pacific Edge Limited is a New Zealand company specializing in the development and marketing of cancer diagnostics and therapy products. The company operates in three business areas: urology, gynecology, and gastroenterology. In urology, they offer Cxbladder, a non-invasive urine test for diagnosing bladder cancer. In gynecology, they have developed the EndometrialScratch test for early detection of endometrial cancer. And in gastroenterology, they provide the ColonoGuard test, a non-invasive blood-based test for diagnosing colon cancer. Their business model involves international marketing of their products and services, partnering with diagnostic and healthcare companies, and establishing a strong presence in the US market. Their competitive advantages are their unique and effective diagnostic technology and their global market presence. Overall, Pacific Edge aims to improve cancer diagnosis and treatment worldwide.
The expected revenue of Pacific Edge is 11.48 M NZD. This figure is based on current financial data and reflects the company's business performance.
The profit cannot currently be calculated for Pacific Edge.
The P/E ratio cannot be calculated for Pacific Edge at the moment.
The price-to-sales ratio (P/S) of Pacific Edge is currently 16.26. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pacific Edge stock.
The Eulerpool Quality Score for Pacific Edge is 4/10.
The ISIN of Pacific Edge is NZPEBE0002S1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pacific Edge is A1JQAD. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pacific Edge is PEB.NZ. The ticker symbol is used to trade Pacific Edge shares on the stock exchange.
Pacific Edge stock
All fundamentals and in-depth analysis of Pacific Edge
Our stock analysis for Pacific Edge stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Edge. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.